Review of NICE Technology Appraisal Guidance No.252; Telaprevir for the treatment of genotype 1 chronic hepatitis C, No.253; Boceprevir for the treatment of genotype 1 chronic hepatitis C, No.330; Sofosbuvir for treating chronic hepatitis C, and No.331; Simeprevir for treating genotype 1 or 4 chronic hepatitis C
Proposal to move existing guidance to the ‘static list’, and to summarise within a new product (‘hepatitis C treatment summary table’)
There are a number of published technology appraisals that provide recommendations on treating hepatitis C therefore it is often difficult to determine which treatment(s) will be most appropriate for prescribing from all the options available.
Consequently, the Medicines and Technologies Programme at NICE has been asked to compile a summary table that will support decision makers and people receiving recommended hepatitis C treatments to identify which treatment options are most appropriate for that individual at the point of prescribing (clinical presentation) presented by genotype and presence of liver cirrhosis or not, rather than by treatment name. This aims to be in line with prescribing decision making approaches, utilising the content of the NICE pathway.
This summary table will include all published technology appraisals and will be updated as and when new recommendations for hepatitis C treatments are made by NICE.
It is proposed that TA252, TA253, TA330 and TA331 are moved to the ‘static list’ of technology appraisals, and that the existing recommendations should be included in the ‘hepatitis C treatment summary table’.
In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators to:
- comment on the proposal to move TA252, TA253, TA330 and TA331 to the ‘static guidance’ list of technology appraisals, and
- comment on the proposal to include TA252, TA253, TA330 and TA331 and all other published TAs for hepatitis C treatments in the forthcoming ‘hepatitis C treatment summary table’
Topics on the static list may be transferred back to the active list for further appraisal if new evidence becomes available that is likely to have a material effect on the last guidance issued.
This page was last updated: 05 May 2017